MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

MINDCURE’s pharmaceutical grade ibogaine would provide researchers access to asustainable, high-quality, reliable, and consistent supply of…

MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company’s First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

VANCOUVER, BC, July 13, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”),…

MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression

MINDCURE will distribute these protocols to therapists through iSTRYM, its digital therapeutics platform. This milestone in protocol development unlocks the…

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

By manufacturing ibogaine, MINDCURE’s research team will have access to a predictable and standardized supply of…

Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer

Dr. Raskin is a psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug…

MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children’s Hospital, as Company Advisor

Dr. Brownstein, an esteemed epidemiologist, researcher at Boston Children’s Hospital and professor at Harvard Medical School, will…

MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM’s Market Launch, Delivering Mental Wealth

MINDCURE is well-positioned to capitalize on its near-term revenue strategy, complete beta testing and launch of…

MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM

Breathwork has shown promise at both replicating the experience of psychedelics and helping patients to integrate…

MINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors

Mr. Wolfe has extensive capital markets and debt and equity financing experience; Ms. Chaikowsky, the COO…

MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions

LUCID’s technology platform unites music, AI and research in neuroscience to create personalized digital music therapy…

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform

Utilizing Speak Ai’s technology, iSTRYM will provide Ai-driven intelligence to help therapists identify the most efficient…

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care…